snyderman nancy lynn MD

SEC source: 0001520262-26-000111 · form4.xml · derivative · entry 6

snyderman nancy lynn MD · CIK 0001675198 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Ordinary Shares · 16,524 shares

Expires 2026-09-14

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_date: These options are fully vested in accordance with their terms.

SEC source: 0001520262-26-000111 · form4.xml · derivative · entry 5

snyderman nancy lynn MD · CIK 0001675198 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Ordinary Shares · 27,948 shares

Expires 2026-09-14

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_date: These options are fully vested in accordance with their terms.

SEC source: 0001520262-26-000111 · form4.xml · nonDerivative · entry 3

snyderman nancy lynn MD · CIK 0001675198 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 15,395

F1 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $50.07 to $50.70. Full information regarding the number of shares sold at each separate price can be provided to the issuer, any security holder of the issuer or the SEC staff upon request.

SEC source: 0001520262-26-000111 · form4.xml · nonDerivative · entry 2

snyderman nancy lynn MD · CIK 0001675198 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 59,867

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001520262-26-000111 · form4.xml · nonDerivative · entry 1

snyderman nancy lynn MD · CIK 0001675198 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 43,343

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001520262-26-000091 · form4.xml · derivative · entry 6

snyderman nancy lynn MD · CIK 0001675198 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Ordinary Shares · 6,142 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one ordinary share.

F1 · price: Each restricted stock unit represents a contingent right to receive one ordinary share.

F4 · derivative.exercise_date: This award is fully vested in accordance with its terms.

F4 · derivative.expiration_date: This award is fully vested in accordance with its terms.

SEC source: 0001520262-26-000091 · form4.xml · nonDerivative · entry 2

snyderman nancy lynn MD · CIK 0001675198 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 15,395

SEC source: 0001520262-26-000091 · form4.xml · nonDerivative · entry 1

snyderman nancy lynn MD · CIK 0001675198 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 16,870

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each restricted stock unit represents a contingent right to receive one ordinary share.

SEC source: 0001520262-26-000091 · form4.xml · derivative · entry 5

snyderman nancy lynn MD · CIK 0001675198 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 5,409

Underlying: Ordinary Shares · 5,409 shares

Expires not disclosed

F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one ordinary share.

F3 · derivative.exercise_date: Shares subject to the award vest (and if applicable, become exercisable) in full on the earlier of the one-year anniversary of the date of grant or the date of the issuer's next annual general meeting of shareholders that occurs at least 50 weeks after the date of grant.

F3 · derivative.expiration_date: Shares subject to the award vest (and if applicable, become exercisable) in full on the earlier of the one-year anniversary of the date of grant or the date of the issuer's next annual general meeting of shareholders that occurs at least 50 weeks after the date of grant.

SEC source: 0001520262-26-000091 · form4.xml · derivative · entry 4

snyderman nancy lynn MD · CIK 0001675198 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 11,538

Underlying: Ordinary Shares · 11,538 shares

Expires 2036-05-20

F3 · derivative.exercise_date: Shares subject to the award vest (and if applicable, become exercisable) in full on the earlier of the one-year anniversary of the date of grant or the date of the issuer's next annual general meeting of shareholders that occurs at least 50 weeks after the date of grant.

SEC source: 0001127602-25-016204 · form4.xml · derivative · entry 4

snyderman nancy lynn MD · CIK 0001675198 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Ordinary Shares · 8,013 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one ordinary share.

F1 · price: Each restricted stock unit represents a contingent right to receive one ordinary share.

F3 · derivative.exercise_date: This award is fully vested in accordance with its terms.

F3 · derivative.expiration_date: This award is fully vested in accordance with its terms.

SEC source: 0001127602-25-016204 · form4.xml · nonDerivative · entry 2

snyderman nancy lynn MD · CIK 0001675198 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 10,728

SEC source: 0001127602-25-016204 · form4.xml · nonDerivative · entry 1

snyderman nancy lynn MD · CIK 0001675198 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 12,652

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each restricted stock unit represents a contingent right to receive one ordinary share.

SEC source: 0001127602-25-015543 · form4.xml · derivative · entry 2

snyderman nancy lynn MD · CIK 0001675198 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 6,142

Underlying: Ordinary Shares · 6,142 shares

Expires not disclosed

F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one ordinary share.

F3 · derivative.exercise_date: Shares subject to the restricted stock unit award vest in full on 5/21/2026.

F3 · derivative.expiration_date: Shares subject to the restricted stock unit award vest in full on 5/21/2026.

SEC source: 0001127602-25-015543 · form4.xml · derivative · entry 1

snyderman nancy lynn MD · CIK 0001675198 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 13,474

Underlying: Ordinary Shares · 13,474 shares

Expires 2035-05-21

F1 · derivative.exercise_date: Shares subject to the stock option award vest and become exercisable in full on 5/21/2026.

SEC source: 0000950170-25-073608 · ownership.xml · derivative · entry 1

snyderman nancy lynn MD · CIK 0001675198 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 32,000

Underlying: Common Stock · 32,000 shares

Expires not disclosed

F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock. The RSUs will vest as to 100% on the earlier of (i) the day before the Issuer's next annual meeting, (ii) May 14, 2026 and (iii) upon a Change in Control as defined in the 2020 Incentive Award Plan.

F1 · derivative.exercise_date: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock. The RSUs will vest as to 100% on the earlier of (i) the day before the Issuer's next annual meeting, (ii) May 14, 2026 and (iii) upon a Change in Control as defined in the 2020 Incentive Award Plan.

F1 · derivative.expiration_date: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock. The RSUs will vest as to 100% on the earlier of (i) the day before the Issuer's next annual meeting, (ii) May 14, 2026 and (iii) upon a Change in Control as defined in the 2020 Incentive Award Plan.

SEC source: 0001562180-24-007710 · primarydocument.xml · derivative · entry 3

snyderman nancy lynn MD · CIK 0001675198 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 10,000 shares

Expires 2029-04-08

F2 · kind: Pursuant to the Merger Agreement, at the Effective Time, each outstanding and unexercised option to purchase shares of the Issuer's common stock granted under the Issuer's 2018 Omnibus Incentive Plan (f/k/a/ Axonics Modulation Technologies, Inc. 2018 Omnibus Incentive Plan) and the Axonics Modulation Technologies, Inc. 2014 Stock Incentive Plan (each such option, a "Company Option"), whether vested or unvested, was canceled and converted into the right to receive an amount in cash, without interest, equal to the product of (a) the amount by which the Merger Consideration exceeds the exercise price per share applicable to such Company Option and (b) the aggregate number of shares of the Issuer's common stock issuable upon exercise of such Company Option, less applicable taxes and authorized deductions.

F2 · price: Pursuant to the Merger Agreement, at the Effective Time, each outstanding and unexercised option to purchase shares of the Issuer's common stock granted under the Issuer's 2018 Omnibus Incentive Plan (f/k/a/ Axonics Modulation Technologies, Inc. 2018 Omnibus Incentive Plan) and the Axonics Modulation Technologies, Inc. 2014 Stock Incentive Plan (each such option, a "Company Option"), whether vested or unvested, was canceled and converted into the right to receive an amount in cash, without interest, equal to the product of (a) the amount by which the Merger Consideration exceeds the exercise price per share applicable to such Company Option and (b) the aggregate number of shares of the Issuer's common stock issuable upon exercise of such Company Option, less applicable taxes and authorized deductions.

F2 · derivative.exercise_date: Pursuant to the Merger Agreement, at the Effective Time, each outstanding and unexercised option to purchase shares of the Issuer's common stock granted under the Issuer's 2018 Omnibus Incentive Plan (f/k/a/ Axonics Modulation Technologies, Inc. 2018 Omnibus Incentive Plan) and the Axonics Modulation Technologies, Inc. 2014 Stock Incentive Plan (each such option, a "Company Option"), whether vested or unvested, was canceled and converted into the right to receive an amount in cash, without interest, equal to the product of (a) the amount by which the Merger Consideration exceeds the exercise price per share applicable to such Company Option and (b) the aggregate number of shares of the Issuer's common stock issuable upon exercise of such Company Option, less applicable taxes and authorized deductions.

SEC source: 0001562180-24-007710 · primarydocument.xml · derivative · entry 2

snyderman nancy lynn MD · CIK 0001675198 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 4,167 shares

Expires 2029-08-22

F2 · kind: Pursuant to the Merger Agreement, at the Effective Time, each outstanding and unexercised option to purchase shares of the Issuer's common stock granted under the Issuer's 2018 Omnibus Incentive Plan (f/k/a/ Axonics Modulation Technologies, Inc. 2018 Omnibus Incentive Plan) and the Axonics Modulation Technologies, Inc. 2014 Stock Incentive Plan (each such option, a "Company Option"), whether vested or unvested, was canceled and converted into the right to receive an amount in cash, without interest, equal to the product of (a) the amount by which the Merger Consideration exceeds the exercise price per share applicable to such Company Option and (b) the aggregate number of shares of the Issuer's common stock issuable upon exercise of such Company Option, less applicable taxes and authorized deductions.

F2 · price: Pursuant to the Merger Agreement, at the Effective Time, each outstanding and unexercised option to purchase shares of the Issuer's common stock granted under the Issuer's 2018 Omnibus Incentive Plan (f/k/a/ Axonics Modulation Technologies, Inc. 2018 Omnibus Incentive Plan) and the Axonics Modulation Technologies, Inc. 2014 Stock Incentive Plan (each such option, a "Company Option"), whether vested or unvested, was canceled and converted into the right to receive an amount in cash, without interest, equal to the product of (a) the amount by which the Merger Consideration exceeds the exercise price per share applicable to such Company Option and (b) the aggregate number of shares of the Issuer's common stock issuable upon exercise of such Company Option, less applicable taxes and authorized deductions.

F2 · derivative.exercise_date: Pursuant to the Merger Agreement, at the Effective Time, each outstanding and unexercised option to purchase shares of the Issuer's common stock granted under the Issuer's 2018 Omnibus Incentive Plan (f/k/a/ Axonics Modulation Technologies, Inc. 2018 Omnibus Incentive Plan) and the Axonics Modulation Technologies, Inc. 2014 Stock Incentive Plan (each such option, a "Company Option"), whether vested or unvested, was canceled and converted into the right to receive an amount in cash, without interest, equal to the product of (a) the amount by which the Merger Consideration exceeds the exercise price per share applicable to such Company Option and (b) the aggregate number of shares of the Issuer's common stock issuable upon exercise of such Company Option, less applicable taxes and authorized deductions.

SEC source: 0001562180-24-007710 · primarydocument.xml · nonDerivative · entry 1

snyderman nancy lynn MD · CIK 0001675198 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

F1 · kind: Reflects the disposition of the reporting person's shares of the Issuer's common stock, upon the consummation of the transactions contemplated by the Agreement and Plan of Merger, dated as of January 8, 2024 (the "Merger Agreement"), among the Issuer, Boston Scientific Corporation ("Parent") and Sadie Merger Sub, Inc., a wholly owned subsidiary of Parent ("Merger Sub"), including the consummation of the merger of Merger Sub with and into the Issuer with the Issuer as the surviving corporation (the "Merger"). Pursuant to the Merger Agreement, at the effective time of the Merger (the "Effective time"), each outstanding share of the Issuer's common stock was canceled and converted automatically into the right to receive $71.00 in cash, without interest (The "Merger Consideration").

F1 · price: Reflects the disposition of the reporting person's shares of the Issuer's common stock, upon the consummation of the transactions contemplated by the Agreement and Plan of Merger, dated as of January 8, 2024 (the "Merger Agreement"), among the Issuer, Boston Scientific Corporation ("Parent") and Sadie Merger Sub, Inc., a wholly owned subsidiary of Parent ("Merger Sub"), including the consummation of the merger of Merger Sub with and into the Issuer with the Issuer as the surviving corporation (the "Merger"). Pursuant to the Merger Agreement, at the effective time of the Merger (the "Effective time"), each outstanding share of the Issuer's common stock was canceled and converted automatically into the right to receive $71.00 in cash, without interest (The "Merger Consideration").

SEC source: 0001562180-24-007659 · primarydocument.xml · nonDerivative · entry 1

snyderman nancy lynn MD · CIK 0001675198 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 14,944

SEC source: 0001127602-24-019603 · form4.xml · derivative · entry 4

snyderman nancy lynn MD · CIK 0001675198 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Ordinary Shares · 6,104 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one ordinary share.

F3 · price: Each restricted stock unit represents a contingent right to receive one ordinary share.

F4 · derivative.exercise_date: This award is fully vested in accordance with its terms.

F4 · derivative.expiration_date: This award is fully vested in accordance with its terms.

SEC source: 0001127602-24-019603 · form4.xml · nonDerivative · entry 3

snyderman nancy lynn MD · CIK 0001675198 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 4,639

SEC source: 0001127602-24-019603 · form4.xml · nonDerivative · entry 2

snyderman nancy lynn MD · CIK 0001675198 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 6,104

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · price: Each restricted stock unit represents a contingent right to receive one ordinary share.

SEC source: 0000950170-24-073648 · ownership.xml · derivative · entry 1

snyderman nancy lynn MD · CIK 0001675198 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 30,000

Underlying: Common Stock · 30,000 shares

Expires 2034-06-12

F1 · derivative.exercise_date: This option vests and becomes exercisable on the earlier of (i) June 13, 2025 (the one-year anniversary of the date of grant) and (ii) the day immediately prior to the date of the Issuer's next annual meeting of stockholders occurring after the date of grant, in either case, subject to the Non-Employee Director's continued service on the Board as a Non-Employee Director through such vesting date.

SEC source: 0001127602-24-017730 · form4.xml · derivative · entry 13

snyderman nancy lynn MD · CIK 0001675198 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 17,492

Underlying: Ordinary Shares · 17,492 shares

Expires 2034-05-31

F7 · derivative.exercise_date: Shares subject to the stock option award vest and become exercisable in full on 5/31/2025.

SEC source: 0001127602-24-017730 · form4.xml · derivative · entry 12

snyderman nancy lynn MD · CIK 0001675198 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 8,013

Underlying: Ordinary Shares · 8,013 shares

Expires not disclosed

F4 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one ordinary share.

F6 · derivative.exercise_date: Shares subject to the restricted stock unit award vest in full on 5/31/2025.

F6 · derivative.expiration_date: Shares subject to the restricted stock unit award vest in full on 5/31/2025.

SEC source: 0001127602-24-017730 · form4.xml · derivative · entry 11

snyderman nancy lynn MD · CIK 0001675198 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 6,104

Underlying: Ordinary Shares · 119 shares

Expires not disclosed

F1 · security: Represents an equity award granted prior to the separation of the issuer's oncology business into Mural Oncology plc (the "Separation"), as adjusted on November 17, 2023 in connection with the Separation (in order to preserve the value associated with the original award) based on the equity adjustment terms set forth in the Employee Matters Agreement filed by the issuer as Exhibit 10.2 to its Current Report on Form 8-K filed with the U.S. Securities and Exchange Commission on November 15, 2023. The exercise price (if any) of the adjusted award is shown in Boxes 2 and 8, the number of shares subject to the adjusted award is shown in Box 9 and the number of shares added to the award pursuant to the adjustment is shown in Box 5.

F4 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one ordinary share.

F4 · price: Each restricted stock unit represents a contingent right to receive one ordinary share.

F5 · derivative.exercise_date: Shares subject to the restricted stock unit award vest in full on 6/29/2024.

F5 · derivative.expiration_date: Shares subject to the restricted stock unit award vest in full on 6/29/2024.

SEC source: 0001127602-24-017730 · form4.xml · derivative · entry 10

snyderman nancy lynn MD · CIK 0001675198 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 12,986

Underlying: Ordinary Shares · 254 shares

Expires 2033-06-29

F1 · security: Represents an equity award granted prior to the separation of the issuer's oncology business into Mural Oncology plc (the "Separation"), as adjusted on November 17, 2023 in connection with the Separation (in order to preserve the value associated with the original award) based on the equity adjustment terms set forth in the Employee Matters Agreement filed by the issuer as Exhibit 10.2 to its Current Report on Form 8-K filed with the U.S. Securities and Exchange Commission on November 15, 2023. The exercise price (if any) of the adjusted award is shown in Boxes 2 and 8, the number of shares subject to the adjusted award is shown in Box 9 and the number of shares added to the award pursuant to the adjustment is shown in Box 5.

F3 · derivative.exercise_date: Shares subject to the stock option award vest and become exercisable in full on 6/29/2024.

SEC source: 0001127602-24-017730 · form4.xml · derivative · entry 9

snyderman nancy lynn MD · CIK 0001675198 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 11,785

Underlying: Ordinary Shares · 231 shares

Expires 2032-07-07

F1 · security: Represents an equity award granted prior to the separation of the issuer's oncology business into Mural Oncology plc (the "Separation"), as adjusted on November 17, 2023 in connection with the Separation (in order to preserve the value associated with the original award) based on the equity adjustment terms set forth in the Employee Matters Agreement filed by the issuer as Exhibit 10.2 to its Current Report on Form 8-K filed with the U.S. Securities and Exchange Commission on November 15, 2023. The exercise price (if any) of the adjusted award is shown in Boxes 2 and 8, the number of shares subject to the adjusted award is shown in Box 9 and the number of shares added to the award pursuant to the adjustment is shown in Box 5.

F2 · derivative.exercise_date: These options are fully vested in accordance with their terms.

SEC source: 0001127602-24-017730 · form4.xml · derivative · entry 8

snyderman nancy lynn MD · CIK 0001675198 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 15,990

Underlying: Ordinary Shares · 313 shares

Expires 2031-06-14

F1 · security: Represents an equity award granted prior to the separation of the issuer's oncology business into Mural Oncology plc (the "Separation"), as adjusted on November 17, 2023 in connection with the Separation (in order to preserve the value associated with the original award) based on the equity adjustment terms set forth in the Employee Matters Agreement filed by the issuer as Exhibit 10.2 to its Current Report on Form 8-K filed with the U.S. Securities and Exchange Commission on November 15, 2023. The exercise price (if any) of the adjusted award is shown in Boxes 2 and 8, the number of shares subject to the adjusted award is shown in Box 9 and the number of shares added to the award pursuant to the adjustment is shown in Box 5.

F2 · derivative.exercise_date: These options are fully vested in accordance with their terms.

SEC source: 0001127602-24-017730 · form4.xml · derivative · entry 7

snyderman nancy lynn MD · CIK 0001675198 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 11,739

Underlying: Ordinary Shares · 230 shares

Expires 2030-12-02

F1 · security: Represents an equity award granted prior to the separation of the issuer's oncology business into Mural Oncology plc (the "Separation"), as adjusted on November 17, 2023 in connection with the Separation (in order to preserve the value associated with the original award) based on the equity adjustment terms set forth in the Employee Matters Agreement filed by the issuer as Exhibit 10.2 to its Current Report on Form 8-K filed with the U.S. Securities and Exchange Commission on November 15, 2023. The exercise price (if any) of the adjusted award is shown in Boxes 2 and 8, the number of shares subject to the adjusted award is shown in Box 9 and the number of shares added to the award pursuant to the adjustment is shown in Box 5.

F2 · derivative.exercise_date: These options are fully vested in accordance with their terms.

SEC source: 0001127602-24-017730 · form4.xml · derivative · entry 6

snyderman nancy lynn MD · CIK 0001675198 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 13,079

Underlying: Ordinary Shares · 256 shares

Expires 2030-05-20

F1 · security: Represents an equity award granted prior to the separation of the issuer's oncology business into Mural Oncology plc (the "Separation"), as adjusted on November 17, 2023 in connection with the Separation (in order to preserve the value associated with the original award) based on the equity adjustment terms set forth in the Employee Matters Agreement filed by the issuer as Exhibit 10.2 to its Current Report on Form 8-K filed with the U.S. Securities and Exchange Commission on November 15, 2023. The exercise price (if any) of the adjusted award is shown in Boxes 2 and 8, the number of shares subject to the adjusted award is shown in Box 9 and the number of shares added to the award pursuant to the adjustment is shown in Box 5.

F2 · derivative.exercise_date: These options are fully vested in accordance with their terms.

SEC source: 0001127602-24-017730 · form4.xml · derivative · entry 5

snyderman nancy lynn MD · CIK 0001675198 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 22,848

Underlying: Ordinary Shares · 448 shares

Expires 2029-05-22

F1 · security: Represents an equity award granted prior to the separation of the issuer's oncology business into Mural Oncology plc (the "Separation"), as adjusted on November 17, 2023 in connection with the Separation (in order to preserve the value associated with the original award) based on the equity adjustment terms set forth in the Employee Matters Agreement filed by the issuer as Exhibit 10.2 to its Current Report on Form 8-K filed with the U.S. Securities and Exchange Commission on November 15, 2023. The exercise price (if any) of the adjusted award is shown in Boxes 2 and 8, the number of shares subject to the adjusted award is shown in Box 9 and the number of shares added to the award pursuant to the adjustment is shown in Box 5.

F2 · derivative.exercise_date: These options are fully vested in accordance with their terms.

SEC source: 0001127602-24-017730 · form4.xml · derivative · entry 4

snyderman nancy lynn MD · CIK 0001675198 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 17,850

Underlying: Ordinary Shares · 350 shares

Expires 2028-05-23

F1 · security: Represents an equity award granted prior to the separation of the issuer's oncology business into Mural Oncology plc (the "Separation"), as adjusted on November 17, 2023 in connection with the Separation (in order to preserve the value associated with the original award) based on the equity adjustment terms set forth in the Employee Matters Agreement filed by the issuer as Exhibit 10.2 to its Current Report on Form 8-K filed with the U.S. Securities and Exchange Commission on November 15, 2023. The exercise price (if any) of the adjusted award is shown in Boxes 2 and 8, the number of shares subject to the adjusted award is shown in Box 9 and the number of shares added to the award pursuant to the adjustment is shown in Box 5.

F2 · derivative.exercise_date: These options are fully vested in accordance with their terms.

SEC source: 0001127602-24-017730 · form4.xml · derivative · entry 3

snyderman nancy lynn MD · CIK 0001675198 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 14,484

Underlying: Ordinary Shares · 284 shares

Expires 2027-05-24

F1 · security: Represents an equity award granted prior to the separation of the issuer's oncology business into Mural Oncology plc (the "Separation"), as adjusted on November 17, 2023 in connection with the Separation (in order to preserve the value associated with the original award) based on the equity adjustment terms set forth in the Employee Matters Agreement filed by the issuer as Exhibit 10.2 to its Current Report on Form 8-K filed with the U.S. Securities and Exchange Commission on November 15, 2023. The exercise price (if any) of the adjusted award is shown in Boxes 2 and 8, the number of shares subject to the adjusted award is shown in Box 9 and the number of shares added to the award pursuant to the adjustment is shown in Box 5.

F2 · derivative.exercise_date: These options are fully vested in accordance with their terms.

SEC source: 0001127602-24-017730 · form4.xml · derivative · entry 2

snyderman nancy lynn MD · CIK 0001675198 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 16,524

Underlying: Ordinary Shares · 324 shares

Expires 2026-09-14

F1 · security: Represents an equity award granted prior to the separation of the issuer's oncology business into Mural Oncology plc (the "Separation"), as adjusted on November 17, 2023 in connection with the Separation (in order to preserve the value associated with the original award) based on the equity adjustment terms set forth in the Employee Matters Agreement filed by the issuer as Exhibit 10.2 to its Current Report on Form 8-K filed with the U.S. Securities and Exchange Commission on November 15, 2023. The exercise price (if any) of the adjusted award is shown in Boxes 2 and 8, the number of shares subject to the adjusted award is shown in Box 9 and the number of shares added to the award pursuant to the adjustment is shown in Box 5.

F2 · derivative.exercise_date: These options are fully vested in accordance with their terms.

SEC source: 0001127602-24-017730 · form4.xml · derivative · entry 1

snyderman nancy lynn MD · CIK 0001675198 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 27,948

Underlying: Ordinary Shares · 548 shares

Expires 2026-09-14

F1 · security: Represents an equity award granted prior to the separation of the issuer's oncology business into Mural Oncology plc (the "Separation"), as adjusted on November 17, 2023 in connection with the Separation (in order to preserve the value associated with the original award) based on the equity adjustment terms set forth in the Employee Matters Agreement filed by the issuer as Exhibit 10.2 to its Current Report on Form 8-K filed with the U.S. Securities and Exchange Commission on November 15, 2023. The exercise price (if any) of the adjusted award is shown in Boxes 2 and 8, the number of shares subject to the adjusted award is shown in Box 9 and the number of shares added to the award pursuant to the adjustment is shown in Box 5.

F2 · derivative.exercise_date: These options are fully vested in accordance with their terms.

SEC source: 0001127602-23-020550 · form4.xml · derivative · entry 3

snyderman nancy lynn MD · CIK 0001675198 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Ordinary Shares · 5,957 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one ordinary share.

F1 · price: Each restricted stock unit represents a contingent right to receive one ordinary share.

F2 · derivative.exercise_date: This award is fully vested in accordance with its terms.

F2 · derivative.expiration_date: This award is fully vested in accordance with its terms.

SEC source: 0001127602-23-020550 · form4.xml · nonDerivative · entry 2

snyderman nancy lynn MD · CIK 0001675198 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 20,783

SEC source: 0001127602-23-020550 · form4.xml · nonDerivative · entry 1

snyderman nancy lynn MD · CIK 0001675198 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 22,213

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each restricted stock unit represents a contingent right to receive one ordinary share.

SEC source: 0000950170-23-031862 · ownership.xml · derivative · entry 1

snyderman nancy lynn MD · CIK 0001675198 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 20,000

Underlying: Common Stock · 20,000 shares

Expires 2033-06-29

F1 · derivative.exercise_date: This option vests and becomes exercisable on June 30, 2024, subject to the Non-Employee Director's continued service on the Board as a Non-Employee Director through such vesting date.

SEC source: 0001127602-23-019633 · form4.xml · derivative · entry 2

snyderman nancy lynn MD · CIK 0001675198 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 5,985

Underlying: Ordinary Shares · 5,985 shares

Expires not disclosed

F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one ordinary share.

F3 · derivative.exercise_date: Shares subject to the restricted stock unit award vest in full on 6/29/2024.

F3 · derivative.expiration_date: Shares subject to the restricted stock unit award vest in full on 6/29/2024.

SEC source: 0001127602-23-019633 · form4.xml · derivative · entry 1

snyderman nancy lynn MD · CIK 0001675198 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 12,732

Underlying: Ordinary Shares · 12,732 shares

Expires 2033-06-29

F1 · derivative.exercise_date: Shares subject to the stock option award vest and become exercisable in full on 6/29/2024.

SEC source: 0001562180-23-005532 · primarydocument.xml · nonDerivative · entry 1

snyderman nancy lynn MD · CIK 0001675198 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 19,944

SEC source: 0001562180-22-006264 · primarydocument.xml · nonDerivative · entry 1

snyderman nancy lynn MD · CIK 0001675198 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 16,944

SEC source: 0001127602-22-019131 · form4.xml · derivative · entry 2

snyderman nancy lynn MD · CIK 0001675198 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 11,554

Underlying: Ordinary Shares · 11,554 shares

Expires 2032-07-07

F3 · derivative.exercise_date: Shares subject to the stock option award vest and become exercisable in full on 7/7/2023.

SEC source: 0001127602-22-019131 · form4.xml · derivative · entry 1

snyderman nancy lynn MD · CIK 0001675198 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,957

Underlying: Ordinary Shares · 5,957 shares

Expires not disclosed

F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one ordinary share.

F2 · derivative.exercise_date: Shares subject to the restricted stock unit award vest in full on 7/7/2023.

F2 · derivative.expiration_date: Shares subject to the restricted stock unit award vest in full on 7/7/2023.

SEC source: 0000899243-22-023331 · doc4.xml · derivative · entry 1

snyderman nancy lynn MD · CIK 0001675198 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 7,250

Underlying: Common Stock · 7,250 shares

Expires 2032-06-15

F1 · derivative.exercise_date: This option vests and becomes exercisable on the earlier of (i) June 16, 2023 (the one-year anniversary of the date of grant) and (ii) the day immediately prior to the date of the Issuer's next annual meeting of stockholders occurring after the date of grant, in either case subject to the Non-Employee Director's continued service on the Board as a Non-Employee Director through such vesting date.

SEC source: 0001127602-22-017639 · form4.xml · derivative · entry 3

snyderman nancy lynn MD · CIK 0001675198 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Ordinary Shares · 7,585 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one ordinary share.

F1 · price: Each restricted stock unit represents a contingent right to receive one ordinary share.

F2 · derivative.exercise_date: This award is fully vested in accordance with its terms.

F2 · derivative.expiration_date: This award is fully vested in accordance with its terms.

SEC source: 0001127602-22-017639 · form4.xml · nonDerivative · entry 2

snyderman nancy lynn MD · CIK 0001675198 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 16,256